Next Article in Journal
Solubility Improvement of Benexate through Salt Formation Using Artificial Sweetener
Next Article in Special Issue
Designing of the Anticancer Nanocomposite with Sustained Release Properties by Using Graphene Oxide Nanocarrier with Phenethyl Isothiocyanate as Anticancer Agent
Previous Article in Journal
Magnetic Nanoparticles Conjugated with Peptides Derived from Monocyte Chemoattractant Protein-1 as a Tool for Targeting Atherosclerosis
Previous Article in Special Issue
Combined Effect of Anticancer Agents and Cytochrome C Decorated Hybrid Nanoparticles for Liver Cancer Therapy
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle
Pharmaceutics 2018, 10(2), 63;

Dual Acting Polymeric Nano-Aggregates for Liver Cancer Therapy

Institute of Science and Technology in Medicine, School of Pharmacy, Keele University, Keele ST5 5BG, UK
College of Pharmacy, Mosul University, Mosul 41002, Iraq
College of Dentistry, University of Basrah, Basrah 61004, Iraq
Author to whom correspondence should be addressed.
Received: 2 May 2018 / Revised: 16 May 2018 / Accepted: 24 May 2018 / Published: 26 May 2018
(This article belongs to the Special Issue Nanotechnology Advances in Cancer Treatment)
Full-Text   |   PDF [4807 KB, uploaded 26 May 2018]   |  


Liver cancer treatments are often hindered by poor drug physicochemical properties, hence there is a need for improvement in order to increase patient survival and outlook. Combination therapies have been studied in order to evaluate whether increased overall efficacy can be achieved. This study reports the combined treatment of liver cancer cells with a combination treatment of chemotherapeutic agent paclitaxel and pro-apoptotic protein cytochrome C. In order to administer both agents in a single formulation, a poly(allylamine)-based amphiphile has been fabricated with the incorporation of a hybrid iron oxide-gold nanoparticle into its structure. Here, the insoluble paclitaxel becomes incorporated into the hydrophobic core of the self-assemblies formed in an aqueous environment (256 nm), while the cytochrome C attaches irreversibly onto the hybrid nanoparticle surface via gold-thiol dative covalent binding. The self-assemblies were capable of solubilising up to 0.698 mg/mL of paclitaxel (700-fold improvement) with 0.012 mg/mL of cytochrome C also attached onto the hybrid iron oxide-gold nanoparticles (HNPs) within the hydrophobic core. The formulation was tested on a panel of liver cancer cells and cytotoxicity was measured. The findings suggested that indeed a significant improvement in combined therapy (33-fold) was observed when compared with free drug, which was double the enhancement observed after polymer encapsulation without the cytochrome C in hepatocellular carcinoma (Huh-7D12) cells. Most excitingly, the polymeric nanoparticles did result in improved cellular toxicity in human endothelian liver cancer (SK-hep1) cells, which proved completely resistant to the free drug. View Full-Text
Keywords: combination therapy; drug delivery; liver cancer; paclitaxel; hybrid nanoparticles combination therapy; drug delivery; liver cancer; paclitaxel; hybrid nanoparticles

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Al-Shakarchi, W.; Alsuraifi, A.; Curtis, A.; Hoskins, C. Dual Acting Polymeric Nano-Aggregates for Liver Cancer Therapy. Pharmaceutics 2018, 10, 63.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top